Clinical Scorecard: Assessing Factors Influencing Tumor Progression in Non-Functioning Pituitary Macroadenomas After Transnasal Transsphenoidal Surgery: A Retrospective Study from a Single Institution

At a Glance

Key Highlights

• Gross total resection (GTR) achieved in 44.3% of patients; 15.1% developed recurrence after GTR.
• Progression of residual tumors correlated significantly with larger preoperative tumor volumes (median 11.6 cm3 vs. 5.81 cm3).
• A preoperative tumor volume cutoff of 7.12 cm3 optimally distinguishes stable from progressive residual tumors (AUC=0.748).

Guideline-Based Recommendations

Diagnosis

• Use MRI with dedicated sellar protocol including contrast-enhanced T1-weighted and T2-weighted sequences for pre- and postoperative tumor volume assessment.
• Classify tumor configuration using Hardy and Knosp scales.
• Histopathological confirmation and proliferation marker assessment (Ki-67, mitotic activity, p53) when available.

Management

• Perform MRI-guided transnasal transsphenoidal surgery aiming for gross total resection when feasible.
• Tailor follow-up and adjuvant therapy decisions based on preoperative and postoperative tumor volumes.
• Consider postoperative cortisol levels as exploratory markers for progression risk.

Monitoring & Follow-up

• Obtain standardized postoperative MRI at 6–12 weeks to establish baseline residual tumor volume.
• Conduct annual surveillance MRI to monitor tumor stability or progression.
• Monitor clinical parameters including visual acuity, visual fields, and hormonal function.

Risks

• Residual tumor volume >7.12 cm3 is associated with higher risk of progression.
• Incomplete resection increases risk of tumor progression or recurrence.
• Potential postoperative hormonal dysfunction requiring endocrinological evaluation.

Patient & Prescribing Data

212 patients with NFPMAs treated surgically between 2007 and 2023

Patients with smaller preoperative tumor volumes (<7.12 cm3) and complete resection have better long-term tumor control; residual tumor volume is a key prognostic factor guiding follow-up intensity.

Clinical Best Practices

• Aim for gross total resection during transnasal transsphenoidal surgery to maximize tumor control.
• Use volumetric MRI assessment pre- and postoperatively to stratify progression risk.
• Implement individualized follow-up protocols based on tumor volume and progression risk.
• Consider early postoperative cortisol measurement as an exploratory prognostic marker.
• Incorporate histopathological proliferation markers when available to refine risk assessment.

References

• Pituitary adenomas prevalence and classification
• WHO classification of pituitary neuroendocrine tumors (PitNETs)
• Surgical management and outcomes of NFPMAs